Second primary malignancies in ruxolitinib-treated myelofibrosis: real-world evidence from 219 consecutive patients

Blood Adv. 2019 Nov 12;3(21):3196-3200. doi: 10.1182/bloodadvances.2019000646.

Abstract

  1. We present real-world data on all ruxolitinib-treated myelofibrosis patients in a 10-million-resident region, with a follow-up of 2 years.

  2. We found no evidence of an increased risk of developing lymphomas.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Biomarkers
  • Duration of Therapy
  • Female
  • Humans
  • Italy / epidemiology
  • Janus Kinase Inhibitors / adverse effects*
  • Janus Kinase Inhibitors / therapeutic use
  • Male
  • Middle Aged
  • Mutation
  • Mutation Rate
  • Neoplasms, Second Primary / diagnosis*
  • Neoplasms, Second Primary / epidemiology
  • Neoplasms, Second Primary / etiology*
  • Nitriles
  • Primary Myelofibrosis / complications*
  • Primary Myelofibrosis / drug therapy
  • Primary Myelofibrosis / epidemiology
  • Primary Myelofibrosis / etiology
  • Pyrazoles / adverse effects*
  • Pyrazoles / therapeutic use
  • Pyrimidines
  • Young Adult

Substances

  • Biomarkers
  • Janus Kinase Inhibitors
  • Nitriles
  • Pyrazoles
  • Pyrimidines
  • ruxolitinib